SPN-812 not checked
Supernus Pharmaceuticals, Inc.
FollowEvery change as it happens, and a Monday email
Trials
2 active
12 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “100mg SPN-812 will be administered once daily and compared to Placebo”In the company’s words, NCT04781140 on ClinicalTrials.gov
- Tested for
- Attention-Deficit/Hyperactivity Disorder (2 trials)
- Main trialPhase 4
- “This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.”In the company’s words, NCT04781140 on ClinicalTrials.gov
- Other names
- Viloxazine extended-release capsules · Low Dose · Low-Medium Dose · Medium-High Dose · High Dose
Other drugs for Attention-Deficit/Hyperactivity Disorder
- CentanafadineOtsuka · Phase 3
- AK-D101Alvogen Korea · Phase 3
- SolriamfetolAxsome Therapeutics, Inc. · Phase 3
- ALKS 7290Alkermes, Inc. · Phase 2
Coming up2
- DecPhase 3 trial completes · ClinicalTrials.gov
- Jan 2028Phase 4 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 17 NovCompletion date moved: 2026-09 to 2026-12 · ClinicalTrials.gov NCT02736656
Trials12
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | Jan 2028 | Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD | |
| Phase 3Active, not recruiting | Dec 2026 | Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) | |
| Phase 4Completed | 23 May 2023 | Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD | |
| Phase 4Completed | 20 Sep 2023 | Evaluation of Viloxazine and Its Metabolite 5-Hydroxy-viloxazine Glucuronide Into Breast Milk in Healthy Lactating Women | |
| Phase 4Completed | 3 Dec 2024 | Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms | |
| Phase 3Completed | 12 Sep 2018 | Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD | |
| Phase 3Completed | 17 Oct 2018 | Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD | |
| Phase 3Completed | 17 Oct 2018 | Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD | |
| Phase 3Completed | 14 Feb 2019 | Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD | |
| Phase 3Completed | 10 Oct 2020 | Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD | |
| Phase 3Completed | 26 Jul 2022 | Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD | |
| Phase 2Completed | 25 Jul 2016 | Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026